 Your new post is loading...
Your new post is loading...
Scoop.it!
Read how Researchers found Molecular Structure of Immune Key Player Implicated in Multiple Sclerosis 
No comment yet.
Sign up to comment
Scoop.it!
Amarantus will use its LymPro Test to evaluate the pharmacodynamic effect of Anavex 2-73 and Anavex Plus on the expression of the biomarker CD69.
Scoop.it!
Healing the CNS
Scoop.it!
nature14252-m1jpg58K30684Alzheimer/'s disease (AD) is a severe age-related neurodegenerative disorder characterized by accumulation of amyloid-[bgr] plaques and neurofibrillary tangles, synaptic and neuronal loss, and cognitive decline. Via Krishan Maggon
Krishan Maggon 's curator insight,
February 19, 2015 3:26 AM
Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s diseaseElizabeta Gjoneska,Andreas R. Pfenning,Hansruedi Mathys,Gerald Quon,Anshul Kundaje,Li-Huei Tsai& Manolis KellisAffiliationsContributionsCorresponding authorsNature 518, 365–369 (19 February 2015) doi:10.1038/nature14252Received 07 January 2014 Accepted 22 January 2015 Published online 18 February 2015
Scoop.it!
RT @BTumour_fighter: Glioblastoma stem cells and stem cell-targeting immunotherapies http://t.co/4NlXAJOa9V
Scoop.it!
Exp Neurol. 2015 Feb 11. pii: S0014-4886(15)00025-4. doi: 10.1016/j.expneurol.2015.02.003. [Epub ahead of print]
Scoop.it!
Costimulatory and coinhibitory receptor–ligand pairs on T cells and APC control the immune response.
Scoop.it!
by Frank Bearoff, Laure K. Case, Dimitry N. Krementsov, Emma H. Wall, Naresha Saligrama, Elizabeth P.
Scoop.it!
Evaluating the Evidence: Direct Comparative Trials in Multiple Sclerosis HCPLive Although 10 disease-modifying agents are available for patients with relapsing-remitting multiple sclerosis (RRMS), and more than 20 years have elapsed since the...
Scoop.it!
http://t.co/ZAhudQeBqo does not seem to address cause of Multiple Sclerosis
Scoop.it!
by Su Ling Leong, Mark G. Hinds, Andrea R. Connor, David P. Smith, Eva Illes-Toth, Chi L. L. Pham, Kevin J.
Scoop.it!
Clin Pharmacol Ther. 2015 Jan 12. doi: 10.1002/cpt.75. [Epub ahead of print]
Scoop.it!
Information on the Cerebrospinal Fluid Disorders Research Group lead by Dr Alexandra Sinclair, Section of Neurotrauma and Neurodegeneration, School of Clinical and Experimental Medicine, The University of Birmingham...
|
Scoop.it!
Dr. David A. Hafler, newly appointed as the inaugural William S.
Scoop.it!
Scientists have proven successful in engineering immune cells to track down and attack glioblastomas, the most common and aggressive type of brain tumor.
Scoop.it!
Study of epigenomic modifications reveals immune basis of Alzheimer's disease.
Scoop.it!
Guidelines for NPSLE patients generally based on physician judgment
Scoop.it!
Abstract Via Krishan Maggon
Krishan Maggon 's curator insight,
February 15, 2015 3:23 AM
Mult Scler Int. 2015;2015:296184. doi: 10.1155/2015/296184. Epub 2015 Jan 8.Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.Bonnan M1.
Scoop.it!
NKT cells can help mediate the protective effects of 1,25-dihydroxyvitamin D3 in experimental autoimmune encep... http://t.co/Xg2P94RhOT
Scoop.it!
The role of cytokines IL-1β, IL-6, and TNFα in epilepsy:
Scoop.it!
Neuroscience. 2014 Jun 6;269:184-91. doi: 10.1016/j.neuroscience.2014.03.049. Epub 2014 Apr 3. Research Support, Non-U.S. Gov't
Scoop.it!
Low CD8+ T Cell Counts Found With Dimethyl Fumarate Multiple Sclerosis Discovery Forum A recent study found that patients taking dimethyl fumarate (Tecfidera) had low counts of CD8+ T cells, though their overall levels of lymphocytes were within...
Scoop.it!
Gilbert C FAURE's insight:
Although the past two decades have seen a profound change in the management of relapsing-remitting multiple sclerosis, almost no disease-modifying treatments exist for primary and secondary progressive multiple sclerosis. In the first of three Series papers in The Lancet Neurology, Hans Lassmann and colleagues provide an overview of the pathological mechanisms underlying progressive multiple sclerosis. Next, Anthony Feinstein and colleagues consider the promise of concurrent, potentially synergistic interventions to alleviate symptoms and improve function. And finally, Daniel Ontaneda and colleagues summarise lessons learned from clinical trials to date, and consider steps that could be taken to facilitate a new era of therapeutic discovery.
Scoop.it!
Author Summary The use of quantitative endophenotypes from cerebrospinal fluid has led to the identification of several genetic variants that alter risk or rate of progression of Alzheimer's disease.
Scoop.it!
A phase I trial of a monoclonal antibody against antiplacental growth factor shows no effect on glioblastoma http://t.co/fceCHjKEO5
|
